The Company has created and continues to develop a rich pipeline of proprietary, flexible, tumour-targeting drug delivery systems with the potential to deliver new or existing and highly potent drugs within a pro-drug vehicle.
This pipeline of new drug candidates utilises unique mechanisms of action. The tumour is specifically targeted, identified and located. Once achieved the novel mechanism releases the active ‘warhead’, thus reducing side effects due to systemic contamination.
It is also believed that Incanthera drugs could be used as a first wave therapy to initiate tumour cell kill once a solid tumour cancer has been diagnosed. The Incanthera programs have the potential to increase the therapeutic window where such oncology treatments can be utilised.